Genscript Biotech Co. (OTCMKTS:GNNSF – Get Rating) was the recipient of a large decline in short interest during the month of March. As of March 31st, there was short interest totalling 364,100 shares, a decline of 60.5% from the March 15th total of 922,500 shares. Based on an average daily trading volume, of 4,400 shares, the short-interest ratio is presently 82.8 days.
Separately, JPMorgan Chase & Co. lowered shares of Genscript Biotech from an “overweight” rating to a “neutral” rating and set a 31.00 price target on the stock. in a research note on Wednesday, January 12th.
GNNSF stock remained flat at $3.06 during midday trading on Friday. Genscript Biotech has a 1-year low of 2.00 and a 1-year high of 5.30. The firm’s fifty day moving average price is 3.36.
Genscript Biotech Corporation, an investment holding company, engages in the manufacture and sale of life science research products and services in North America, Europe, China, Japan, the other Asia Pacific regions, and internationally. It operates through four segments: Life Science Services and Products, Biologics Development Services, Industrial Synthetic Biology Products, and Cell Therapy.
- Get a free copy of the StockNews.com research report on Genscript Biotech (GNNSF)
- Institutions And Analysts Drive UnitedHealth Group Higher
- MarketBeat: Week in Review 4/11 – 4/15
- Three Beaten Down Mega Caps The Analysts Are Upgrading
- Top 3 Safe Stocks for Conservative Investors
- Array Technologies Stock Giving Another Ground Floor Entry
Receive News & Ratings for Genscript Biotech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Genscript Biotech and related companies with MarketBeat.com's FREE daily email newsletter.